Clinical Trials Logo
  1. Home
  2. Carcinoma, Small Cell Lung
  3. NCT02736916

HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer

Carcinoma, Small Cell Lung Clinical Trial

Official title:
Hippocampal-Sparing Whole-Brain Radiation Therapy for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer

Clinical Trial Summary

Prophylactic cranial irradiation (PCI) is an important treatment modality of patients with limited stage small cell lung cancer (LD-SCLC). However, PCI is also associated with several side effects, such as decline in memory and other cognitive functions. This provides the rationale to explore the clinical feasibility of hippocampal avoidance during WBRT. Previous studies have demonstrated the dosimetric capabilities of IMRT to conformally avoid the hippocampus without detriment to the radiation dose the remaining brain receives. The aims of this study is to evaluate the therapy efficacy and the safety profile of hippocampal-sparing whole-brain radiation therapy (HS-WBRT) for PCI in patients with LD-SCLC.

Clinical Trial Description

Chemotherapy plus thoracic radiation followed by prophylactic cranial irradiation (PCI) is the standard of care in management of limited stage small cell lung cancer patients. However, whole brain radiation therapy (WBRT) is also associated with many side effects including consolidation of new memory, poor attention span/concentration, visual spatial difficulties, difficulty with executive planning, and poor fine motor control. There exists significant preclinical and clinical evidence that radiation induced injury to the hippocampus correlates with neurocognitive decline of patients who received WBRT. Reducing radiation dose to the hippocampus during WBRT has been postulated as an approach to mitigate neurocognitive impairment. The present study hypothesize that hippocampal sparing PCI will allow improved performance on tests of short term memory and executive function compared to a historical control receiving the same dose of conventional PCI. The primary objective of this study is to evaluate performance on the Hopkins Verbal Learning Test-Revised for delayed recall at 6 months following hippocampal-sparing PCI relative to the historical control. Secondary objectives are to estimate: composite cognitive function following hippocampal-sparing PCI relative to the historical control and the rate of metastases in the hippocampus at 2 years following hippocampal-sparing PCI. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02736916
Study type Interventional
Source General Hospital of Ningxia Medical University
Contact Yan-Yang Wang, M.D.
Phone 86-951-6743315
Email fdwyy1981@hotmail.com
Status Recruiting
Phase N/A
Start date March 2016
Completion date December 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT00037713 - Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Phase 3
Terminated NCT00637624 - N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy N/A
Completed NCT00308529 - Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer Phase 2
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Active, not recruiting NCT01306045 - Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Phase 2
Terminated NCT00435578 - Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma Phase 2
Completed NCT00294931 - Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Terminated NCT00265200 - Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer Phase 2
Completed NCT00270166 - The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy Phase 3
Completed NCT02936323 - PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Phase 1/Phase 2
Terminated NCT03699956 - RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer Phase 3
Completed NCT00263731 - Metabolomic Analysis of Lung Cancer
Active, not recruiting NCT04622228 - Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04253145 - Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer. Phase 1/Phase 2
Terminated NCT04308785 - A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05566041 - A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer Phase 3
Completed NCT03083691 - BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer Phase 2
Not yet recruiting NCT03871205 - Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer Phase 1